IL2 and neoplasm: Together, these results show that progressive expansion of CD8 CAR-T cells with IL-2 (normally performed in the clinic) compromises their fitness and attenuates their anti-tumor efficacy, but the enhanced metabolic fitness provided by the loss of MCJ preserves their anti-tumor activity and overall in vivo efficacy.